SG&A Efficiency Analysis: Comparing Merus N.V. and Protagonist Therapeutics, Inc.

Biotech Giants: SG&A Strategies Unveiled

__timestampMerus N.V.Protagonist Therapeutics, Inc.
Wednesday, January 1, 201438523271860000
Thursday, January 1, 20158396562963000
Friday, January 1, 201644781456961000
Sunday, January 1, 20171643232411779000
Monday, January 1, 20181189087113697000
Tuesday, January 1, 20193411000015749000
Wednesday, January 1, 20203578100018638000
Friday, January 1, 20214089600027196000
Saturday, January 1, 20225220000031739000
Sunday, January 1, 20235983600033491000
Loading chart...

Data in motion

SG&A Efficiency: A Tale of Two Biotech Innovators

In the competitive world of biotechnology, managing operational costs is crucial for success. Over the past decade, Merus N.V. and Protagonist Therapeutics, Inc. have demonstrated distinct strategies in handling their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Merus N.V. saw a staggering 1,450% increase in SG&A expenses, peaking at nearly $60 million in 2023. In contrast, Protagonist Therapeutics, Inc. experienced a more moderate rise of 1,700%, reaching approximately $33 million in the same year.

This divergence highlights Merus N.V.'s aggressive expansion and investment in administrative capabilities, while Protagonist Therapeutics, Inc. maintains a more conservative approach. Understanding these trends offers valuable insights into each company's strategic priorities and operational efficiency. As the biotech landscape evolves, these financial strategies will play a pivotal role in shaping their future trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025